5 Best Psychedelic Stocks to Buy According to Analysts

2. Cybin D/B/A Helus Pharma (NASDAQ:HELP)

Price Target Upside: 430.68%

Cybin D/B/A Helus Pharma (NASDAQ:HELP) is one of the best psychedelic stocks on our list.

TheFly reported on July 1 that Canaccord analyst Sumant Kulkarni lowered the price target on HELP to $42 from $45 while maintaining a Buy rating on the shares. The firm highlighted Helus Pharma’s lead candidate, HLP003, a deuterated psilocin analog currently being evaluated in a Phase 3 program for adjunctive treatment of major depressive disorder (MDD). Canaccord expects significant potential upside from upcoming Phase 3 APPROACH trial results for HLP003, which are anticipated in the fourth quarter of 2026.

In other news, earlier on June 24, Cybin D/B/A Helus Pharma (NASDAQ:HELP) announced the pricing of an underwritten public offering involving 10,309,280 common shares. The shares were offered for $4.85 each, generating approximately $50 million in gross proceeds for the company. The offering was expected to close on June 25. Cantor and Barclays served as joint bookrunning managers for the transaction, while Bloom Burton Securities and Lucid Capital Markets acted as lead managers. The capital raise is intended to support HELP’s ongoing operations and advancement of its development programs.

Cybin D/B/A Helus Pharma (NASDAQ:HELP) is a clinical-stage neuropsychiatry company developing psychedelic-based therapies and novel serotonergic agonists for mental health conditions such as major depressive disorder and generalized anxiety disorder.